Compare SMBC & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SMBC | LBRX |
|---|---|---|
| Founded | 1887 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 742.0M | 602.6M |
| IPO Year | 2011 | N/A |
| Metric | SMBC | LBRX |
|---|---|---|
| Price | $66.37 | $27.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $68.00 | $47.00 |
| AVG Volume (30 Days) | 75.6K | ★ 242.1K |
| Earning Date | 04-27-2026 | 05-09-2026 |
| Dividend Yield | ★ 1.50% | N/A |
| EPS Growth | ★ 17.19 | N/A |
| EPS | ★ 3.00 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.09 | N/A |
| Revenue Next Year | $5.69 | N/A |
| P/E Ratio | $22.26 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $47.60 | $13.40 |
| 52 Week High | $68.20 | $27.55 |
| Indicator | SMBC | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 66.28 | 61.34 |
| Support Level | $59.32 | $22.39 |
| Resistance Level | $68.20 | N/A |
| Average True Range (ATR) | 1.47 | 1.68 |
| MACD | 0.29 | 0.18 |
| Stochastic Oscillator | 76.91 | 96.71 |
Southern Missouri Bancorp Inc is a USA-based holding company for Southern Missouri Savings Bank. The principal business of the bank consists of attracting retail deposits from the general public and using such deposits along with wholesale funding from the Federal Home Loan Bank of Des Moines, and to a lesser extent, brokered deposits, to invest in one- to four-family residential mortgage loans, mortgage loans secured by commercial real estate, commercial non-mortgage business loans, and consumer loans. It is engaged in providing the range of banking and financial services to individuals and corporate customers in its market areas. The company derives revenue principally from interest earned on loans, debt securities, bank card interchange fees, loan late charges and another fee income.
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.